Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $341000.0.

  • CytomX Therapeutics' Other Accumulated Expenses rose 1678.08% to $341000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $341000.0, marking a year-over-year increase of 1678.08%. This contributed to the annual value of $490000.0 for FY2024, which is 5605.1% up from last year.
  • Per CytomX Therapeutics' latest filing, its Other Accumulated Expenses stood at $341000.0 for Q3 2025, which was up 1678.08% from $111000.0 recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Other Accumulated Expenses peaked at $943000.0 during Q1 2022, and registered a low of $63000.0 during Q1 2025.
  • For the 5-year period, CytomX Therapeutics' Other Accumulated Expenses averaged around $403526.3, with its median value being $341000.0 (2025).
  • As far as peak fluctuations go, CytomX Therapeutics' Other Accumulated Expenses soared by 60151.52% in 2021, and later crashed by 8615.38% in 2025.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Other Accumulated Expenses stood at $713000.0 in 2021, then plummeted by 63.39% to $261000.0 in 2022, then increased by 20.31% to $314000.0 in 2023, then soared by 56.05% to $490000.0 in 2024, then tumbled by 30.41% to $341000.0 in 2025.
  • Its Other Accumulated Expenses was $341000.0 in Q3 2025, compared to $111000.0 in Q2 2025 and $63000.0 in Q1 2025.